WO1995025169A1 - Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes - Google Patents
Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes Download PDFInfo
- Publication number
- WO1995025169A1 WO1995025169A1 PCT/ES1994/000027 ES9400027W WO9525169A1 WO 1995025169 A1 WO1995025169 A1 WO 1995025169A1 ES 9400027 W ES9400027 W ES 9400027W WO 9525169 A1 WO9525169 A1 WO 9525169A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- insulin
- cells
- chimeric
- chimeric gene
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 56
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 15
- 238000001415 gene therapy Methods 0.000 title claims abstract description 13
- 239000002299 complementary DNA Substances 0.000 title claims description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 20
- 230000014509 gene expression Effects 0.000 claims abstract description 16
- 230000009261 transgenic effect Effects 0.000 claims abstract description 13
- 230000004927 fusion Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 210000000496 pancreas Anatomy 0.000 claims abstract description 8
- 239000013604 expression vector Substances 0.000 claims abstract description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 48
- 108090001061 Insulin Proteins 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 28
- 102000004877 Insulin Human genes 0.000 claims description 24
- 229940125396 insulin Drugs 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 12
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 3
- 108020004635 Complementary DNA Proteins 0.000 claims description 3
- 238000010804 cDNA synthesis Methods 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 claims 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 16
- 108700024394 Exon Proteins 0.000 abstract description 2
- 108091092195 Intron Proteins 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101150045799 PEPCK gene Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000002933 immunoreactive insulin Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000001890 gluconeogenic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001019 normoglycemic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Definitions
- the present invention relates firstly to a chimeric gene that uses the insulin gene or cDNA (complementary DNA) directed by a promoter or promoter fusion.
- a chimeric gene formed by the fusion of the promoter of P-enolpiruvato carboxykinase to the structural gene of human insulin, which allows the production of human insulin, in a physiologically regulated manner, in a tissue other than the pancreas.
- the invention also relates to other objects described below.
- IDDM insulin-dependent diabetes mellitus
- Gene therapy involves the transfer of genetic material into a patient's cells in order to treat a disease.
- Different gene therapy approaches are currently being developed, based on the introduction of genes directly into animals or into cells - which are subsequently transplanted.
- the most important goal is not to successfully transplant cells that express the gene into an animal, but to get the gene to be expressed in a regulated and physiological manner.
- the choice of a good promoter that directs the expression of the appropriate gene is crucial in order to obtain adequate plasma levels of the corresponding protein.
- the subject of the invention is a chimeric gene that uses the insulin gene or cDNA (complementary DNA) directed by a promoter or fusion of promoters, preferably adjustable and activated by the diabetic process.
- the object of the invention is a chimeric gene that is obtained by the fusion of the human insulin gene to the P-enolpyruvate carboxy kinase (PEPCK) promoter.
- PPCK P-enolpyruvate carboxy kinase
- P-enolpiruvato carboxykinase is a key enzyme in the control of the gluconeogenic pathway, and is found mainly in the liver, kidney, jejunum and adipose tissue.
- the activity of this enzyme is regulated at the level of its gene expression (Hanson, RW, et al. (1976) Glycogenesis: I ts Regulation in mammalian Species. John Wiley & Sons, Inc., New York).
- PEPCK gene expression It is finely regulated by hormones. In the fragment of the PEPCK promoter used (-550 bp to +73 bp) sequences that respond to cAMP, glucocorticoids and insulin have been described (ynshaw-Boris, A.
- This fragment of the PEPCK promoter is capable of directing the expression of the bovine growth hormone gene in a regulated and tissue-specific manner in transgenic animals (McGrane, MM, et al (1988) J. Biol. Chem. 263 , 11443-11451; Short, MK, et al. (1992) Mol. Cell. Biol. 12, 1007-1020; Eisenberger, CL (1992) Mol. Cell. Biol. 12, 1396-1403).
- the chimeric gene will be transcribed, but, when enough has been synthesized, the insulin itself will inhibit the PEPCK promoter that directs its expression.
- the invention is therefore aimed at creating a chimeric PEPCK / insulin gene.
- the fragment corresponding to the insulin gene conserves 170 bp of the 5 'flanking zone goes.
- the chimeric PEPCK / insulin gene contains two initiations of transcription, one corresponding to the insulin promoter, and the other to the PEPCK promoter. It is actually a chimeric promoter, to which the part of the PEPCK promoter confers tissue specificity (mainly liver, kidney, jejunum and adipose).
- This chimeric gene has been introduced into hepato a cells in culture and hepatocytes in primary culture by transient transfection, observing that insulin-specific mRNA cells in liver and immunoreactive insulin appeared in these culture media.
- a subject of the invention is also a method of fusion of promoters or gene regulatory elements that allow insulin to be expressed in cell types other than pancreatic ⁇ cells.
- the part of the PEPCK promoter confers tissue specificity (mainly liver, kidney, jejunum and adipose).
- a subject of this invention is also an expression vector that allows insulin to be expressed in cells other than pancreatic ⁇ cells, more particularly, a pPCK / Ins plasmid vector and a vPCK / Ins retroviral vector. These vectors allow the expression of the chimeric gene in cells.
- Other viral expression vectors adenovirus, herpes virus, papillonavirus, etc.
- non-viral can also be used.
- a subject of the invention is also a transgenic animal that expresses the chimeric gene described above, as well as a cell type originating from this transgenic animal.
- Transgenic mice have been obtained in the laboratory by the technique of microinjection of the chimeric gene to fertilized mouse ovules before the fusion of the two female and male pronuclei. The animals obtained were found to be healthy and normoglycemic, indicating that there is good control in the regulation of the chimeric gene.
- Another object of the invention is the chromosome of the transgenic animal that contains the chimeric gene "" described above.
- the invention aims at a chimeric gene of the type described above, for use in the gene therapy of diabetes, more specifically, for the use in the gene therapy of diabetes in tissues other than the pancreas in mammals, particularly in the human species.
- transgenic animal of the type described for use in the development of gene therapy protocols.
- Figure 1 depicts the construction of the PEPCK / Insulin chimeric gene from plasmid pB7.0 and the human insulin gene
- Figure 2 represents the structure of the chimeric PEPCK / insulin gene na
- Figure 3 represents the process of obtaining the retroviral vector vPCK / Ins from plasmid pPCK / - Ins.
- the plasmid pB7.0 containing the entire PEPCK gene was started.
- the 5 * flanking zone of this gene was obtained by digestion with the enzymes Xbal and BglII (fragment -460 bp at +73 bp).
- This fragment was then subcloned into the polylinker of plasmid pTZ18.
- this plasmid was digested with Xbal and BglII and the promoter fragment was subsequently ligated to these targets.
- the PEPCK promoter had been subcloned in pTZ18 and there were still other targets in the polylinker that could be used later.
- the human insulin gene was introduced.
- Plasmid pTZ18 which contained the PEPCK promoter, was digested with BglII, target located at the end of the promoter ( 3 'end), and with Sphl, target located in the polylinker. This linearized plasmid was ligated with the BglII / -Sphl fragment of the insulin gene, and the chimeric PEPCK / insulin gene was obtained, subcloned into pTZ18 (Fig. 1). This plasmid was named pPCK / Ins.
- Fig. 2 the structure of the chimeric PEPCK / insulin gene is presented in detail.
- the PEPCK promoter fragment -460 bp at +73 bp
- This insulin promoter fragment contains the elements recognized by the general machinery of transcription and an element of response to cAMP (which induces gene expression).
- the human insulin gene contains three exons (two encoders, El and E2) and two introns (A and B). In position 5 'with respect to intron A is the "cap site" and in 3' of the last exon is the polyadenylation zone (Fig. 2).
- This chimeric gene has been introduced into hepatoma cells in culture and hepatocytes in primary culture by transient transfection of the plasmid pPCK / I-ns, being observed that it appeared in these specific insulin mRNA cells, and immunoreactive insulin in the medium. of cultivation
- the Clal fragment of pl2NPCK / I-ns, containing the chimeric gene was obtained and introduced into the Cia I target of the retroviral vector pLJ (-SV40) (derived from the parental vector pLJ (Korman, AJ, et al. (1987 ) Proc. Nati. Acad. Sci. USA 84. 2150-2154)).
- This vector was introduced into psi-2 cells (Mann, R., (1983) Cell 33, 153-159) by precipitation with calcium phosphate.
- the cells were exposed to the G418 selection antibiotic 48 hours after the transfer, and those that were positive for vector integration survived the toxic. These cells were kept in culture for a month, and when they reached confluence the culture medium, which contained the defective virions, was collected.
- the process of obtaining a transgenic animal that expresses the chimeric gene PEPCK / Insulin is briefly explained below. Once it was verified that the chimeric gene was functional by transfection of cells in culture, the chimeric gene (Xbal-Sphl fragment) was microinjected into fertilized mouse ovules before the fusion of the two female and male pronuclei according to the method described by Wagner, et al. (1981) Proc. Nati Acad. Sci. USA 78, 5016). These embryos were subsequently transferred to a recipient mother.
- transgenic animals From the animals obtained, DNA was isolated from a tail fragment and then the presence of the transgene was analyzed by Southern blotting and subsequent hybridization with a specific probe containing a fragment of the micro-injected chimeric gene. With transgenic animals colonies have been established, in which the expression of the chimeric gene has been analyzed. Thus the obtained transgenic animals express the transgene in the tissues where the PEPCK is normally expressed. The animals obtained turned out to be healthy and norraoglycemic, indicating therefore that there is good control in the regulation of the chimeric gene.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Environmental Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES1994/000027 WO1995025169A1 (es) | 1994-03-14 | 1994-03-14 | Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes |
US08/553,576 US6137029A (en) | 1994-03-14 | 1994-03-14 | PEPCK-insulin gene construct and transgenic mouse |
AU62588/94A AU6258894A (en) | 1994-03-14 | 1994-03-14 | Chimeric gene using the gene or cdna of insuline, specially for the gene therapy of diabetes |
US09/565,728 US6432676B1 (en) | 1994-03-14 | 2000-05-05 | Chimeric gene using the gene or cDNA of insulin, specially for the gene therapy of diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES1994/000027 WO1995025169A1 (es) | 1994-03-14 | 1994-03-14 | Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/565,728 Continuation US6432676B1 (en) | 1994-03-14 | 2000-05-05 | Chimeric gene using the gene or cDNA of insulin, specially for the gene therapy of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995025169A1 true WO1995025169A1 (es) | 1995-09-21 |
Family
ID=8284860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES1994/000027 WO1995025169A1 (es) | 1994-03-14 | 1994-03-14 | Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes |
Country Status (3)
Country | Link |
---|---|
US (1) | US6137029A (es) |
AU (1) | AU6258894A (es) |
WO (1) | WO1995025169A1 (es) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017994A1 (es) * | 1995-11-16 | 1997-05-22 | Universidad Autonoma De Barcelona | Tratamiento de la diabetes con un gen de glucoquinasa |
WO2002049423A1 (es) * | 2000-12-20 | 2002-06-27 | Universitat Autonoma De Barcelona | Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus |
ES2190311A1 (es) * | 2000-08-31 | 2003-07-16 | Univ Barcelona Autonoma | Gen quimerico que comprende el gen o adnc de la fructoquinasa para el desarrollo de aproximaciones terapeuticas a la intolerancia hereditaria a la fructosa. |
US11753647B2 (en) | 2020-07-24 | 2023-09-12 | Samsung Electronics Co., Ltd. | Isolated polynucleotide including promoter region, host cell including the same and method of expressing a target gene using the host cell |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432676B1 (en) * | 1994-03-14 | 2002-08-13 | Universitat Autonoma De Barcelona | Chimeric gene using the gene or cDNA of insulin, specially for the gene therapy of diabetes |
EP3626832A3 (en) | 2014-11-25 | 2020-05-13 | The Brigham and Women's Hospital, Inc. | Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease |
US10683552B2 (en) | 2014-11-25 | 2020-06-16 | Presidents And Fellows Of Harvard College | Clonal haematopoiesis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988010304A1 (en) * | 1987-06-16 | 1988-12-29 | Edison Animal Biotechnology Center | Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase |
-
1994
- 1994-03-14 WO PCT/ES1994/000027 patent/WO1995025169A1/es active Application Filing
- 1994-03-14 AU AU62588/94A patent/AU6258894A/en not_active Abandoned
- 1994-03-14 US US08/553,576 patent/US6137029A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988010304A1 (en) * | 1987-06-16 | 1988-12-29 | Edison Animal Biotechnology Center | Dietary and hormonal regulation of expression of exogenous genes in transgenic animals under control of the promoter of the gene for phosphoenolpyruvate carboxykinase |
Non-Patent Citations (3)
Title |
---|
ALFONS VALERA ET AL.: "Regulated expression of human insulin in the liver of transgenic mice corrects diabetic alterations", FASEB JOURNAL, vol. 8, no. 6, 1 April 1994 (1994-04-01), BETHESDA, MD US, pages 440 - 447 * |
JOURNAL OF CELLULAR BIOCHEMISTRY KEYSTONE SYMPOSIA ON MOLECULAR & CELLULAR BIOLOGY. Suplemento 17E, 1993 29 Marzo-25 Abril, 1993, página 252 * |
JOURNAL OF CELLULAR BIOCHEMISTRY KEYSTONE SYMPOSIA ON MOLECULAR & CELLULAR BIOLOGY. Suplemento 18A, 1994 4-23 Enero, 1994, página 145 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017994A1 (es) * | 1995-11-16 | 1997-05-22 | Universidad Autonoma De Barcelona | Tratamiento de la diabetes con un gen de glucoquinasa |
ES2190311A1 (es) * | 2000-08-31 | 2003-07-16 | Univ Barcelona Autonoma | Gen quimerico que comprende el gen o adnc de la fructoquinasa para el desarrollo de aproximaciones terapeuticas a la intolerancia hereditaria a la fructosa. |
WO2002049423A1 (es) * | 2000-12-20 | 2002-06-27 | Universitat Autonoma De Barcelona | Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus |
ES2170720A1 (es) * | 2000-12-20 | 2002-08-01 | Univ Barcelona Autonoma | Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus. |
US11753647B2 (en) | 2020-07-24 | 2023-09-12 | Samsung Electronics Co., Ltd. | Isolated polynucleotide including promoter region, host cell including the same and method of expressing a target gene using the host cell |
Also Published As
Publication number | Publication date |
---|---|
US6137029A (en) | 2000-10-24 |
AU6258894A (en) | 1995-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Neuhaus et al. | Use of alternate promoters for tissue-specific expression of the gene coding for connexin32 | |
JP5320546B2 (ja) | Tol1因子のトランスポザーゼ及びそれを用いたDNA導入システム | |
Kim et al. | Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth | |
US20090042299A1 (en) | Vectors and methods for tissue specific synthesis of proteins in eggs of transgenic hens | |
JP4493492B2 (ja) | 脊椎動物における遺伝子移入のためのトランスポゾンベクターであるFrogPrince | |
ES2774491T3 (es) | Terapia génica con insulina basada en hepatocitos para la diabetes | |
US20060294610A1 (en) | Alpha1-3 galactosyltransferase gene and promoter | |
EP1890708A1 (en) | Glucose inducible insulin expression and methods of treating diabetes | |
CN111500639A (zh) | Stat3线粒体定位条件性基因敲入小鼠模型的构建方法 | |
WO1995025169A1 (es) | Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes | |
US8952214B2 (en) | Animal model for chronic obstructive pulmonary disease and cystic fibrosis | |
US20070083940A1 (en) | Transformed silkworm producing human collagen | |
WO2004022741A1 (ja) | 哺乳類人工染色体 | |
US20020138862A1 (en) | Protein tyrosine phosphatase-1B (PTP-1B) deficient mice and assays for PTP-1B modulators | |
Ishino et al. | Adenovirus-mediated gene transfer to keratinocytes–a review | |
US6432676B1 (en) | Chimeric gene using the gene or cDNA of insulin, specially for the gene therapy of diabetes | |
JP4811765B2 (ja) | 外来遺伝子の誘導発現の制御が可能な発現ベクター | |
KR20070007894A (ko) | 항비만약 | |
CN115279184A (zh) | B4galt1介导的功能的啮齿动物模型 | |
AU2009240404A2 (en) | Abi1/Hssh3bp1 conditional knockout mouse | |
WO2000024759A1 (en) | Systemic delivery of gene products via skin | |
US20060156423A1 (en) | Method of screening antiobesity agents and animal model of obesity | |
JP2001524819A (ja) | インスリンをコードする遺伝子の発現が抑制されている非ヒト・トランスジェニック動物 | |
CN114854791A (zh) | 一种新型CRISPR-Cas9系统载体及其应用 | |
US20010007656A1 (en) | Treatment of diabetes with transcription factor gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08553576 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |